Dr Reddy's stock: USFDA closes Hyderabad inspection with VAI status
Published on 11/20/2026 at 01:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory update at Hyderabad facility
- The USFDA closed its GMP inspection of Dr. Reddy's FTO-3 formulations facility.
- The inspection outcome received a Voluntary Action Indicated classification.
- The company had disclosed the inspection to stock exchanges on August 14, 2026.
Dr. Reddy's Laboratories said on Saturday, November 14, 2026, that the US Food and Drug Administration had closed its Good Manufacturing Practices inspection of the FTO-3 formulations facility in Bachupally, Hyderabad. The regulator classified the outcome as Voluntary Action Indicated, or VAI.
Business Standard reported the development on Sunday, November 15. The company said the USFDA had officially concluded the inspection under 21 CFR 20.64(d)(3).
What the inspection outcome means
VAI is a regulatory classification indicating that the inspection has been closed while the regulator has identified observations requiring attention. The report does not state that the facility was shut down or that production was halted.
Dr. Reddy's had previously informed stock exchanges about the inspection on August 14, 2026. The latest filing therefore marks the conclusion of that inspection process rather than the start of a new inspection.
Business model and market reach
Dr. Reddy's Laboratories develops, manufactures and markets generic medicines, biosimilars, active pharmaceutical ingredients, innovative medicines and consumer health products. Its activities span branded and unbranded generics, API and services, innovative medicines and consumer health solutions. The company serves patients and partners across global markets from its base in India.
Dr. Reddy's Laboratories at a glance
- Company: Dr. Reddy's Laboratories Limited
- ISIN: INE089A01023
- Regulatory event: USFDA closure of the FTO-3 GMP inspection
- Classification: Voluntary Action Indicated
- Facility: Bachupally, Hyderabad, India
- Event date: November 14, 2026
India's pharmaceutical sector sits within the broader domestic equity market represented by the BSE Sensex.
